DPW
SMMT icon

DiNuzzo Private Wealth’s Summit Therapeutics SMMT Stock Holding History

DiNuzzo Private Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18
Closed -$427 – 1402
2025
Q3 		$427 Sell
18
-7
-28% -$170 ﹤0.01% 1126
2025
Q2 		$532 Hold
25
– – ﹤0.01% 1054
2025
Q1 		$483 Buy
+25
New +$502 ﹤0.01% 1059

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

DiNuzzo Private Wealth's SMMT Position: Q4 2025 in Review

DiNuzzo Private Wealth sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 18 shares — an estimated $427 sold.

DiNuzzo Private Wealth first reported a position in SMMT in Q1 2025 and held it in 3 quarters. The position peaked at $532 in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • DiNuzzo Private Wealth reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DiNuzzo Private Wealth sold 18 Summit Therapeutics shares in Q4 2025, an estimated $427.
  • DiNuzzo Private Wealth first reported a position in Summit Therapeutics in Q1 2025 and held it in 3 quarters.
  • DiNuzzo Private Wealth's Summit Therapeutics position peaked at $532 in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on DiNuzzo Private Wealth's 13F filing for Q4 2025, filed 16 Jan 2026.